Results 221 to 230 of about 3,241,751 (271)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Conflict of Interest Disclosure in Oncology: Preliminary Insights From the Global ONCOTRUST-1 Cross-Sectional Study. [PDF]

open access: yesJCO Glob Oncol
El Bairi K   +18 more
europepmc   +1 more source

Conflict of interest in biomedical publications

open access: yesIndian Journal of Ophthalmology, 2007
Nayak Barun
doaj  

Home - About - Disclaimer - Privacy